JP2024542096A5 - - Google Patents

Info

Publication number
JP2024542096A5
JP2024542096A5 JP2024526578A JP2024526578A JP2024542096A5 JP 2024542096 A5 JP2024542096 A5 JP 2024542096A5 JP 2024526578 A JP2024526578 A JP 2024526578A JP 2024526578 A JP2024526578 A JP 2024526578A JP 2024542096 A5 JP2024542096 A5 JP 2024542096A5
Authority
JP
Japan
Prior art keywords
disease
syndrome
autoimmune
fusion protein
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542096A (ja
Filing date
Publication date
Priority claimed from GBGB2115803.5A external-priority patent/GB202115803D0/en
Application filed filed Critical
Publication of JP2024542096A publication Critical patent/JP2024542096A/ja
Publication of JP2024542096A5 publication Critical patent/JP2024542096A5/ja
Pending legal-status Critical Current

Links

JP2024526578A 2021-11-03 2022-11-03 新規タンパク質 Pending JP2024542096A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2115803.5 2021-11-03
GBGB2115803.5A GB202115803D0 (en) 2021-11-03 2021-11-03 Novel proteins
PCT/GB2022/052764 WO2023079278A1 (en) 2021-11-03 2022-11-03 Novel proteins

Publications (2)

Publication Number Publication Date
JP2024542096A JP2024542096A (ja) 2024-11-13
JP2024542096A5 true JP2024542096A5 (cg-RX-API-DMAC7.html) 2025-10-30

Family

ID=78828504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526578A Pending JP2024542096A (ja) 2021-11-03 2022-11-03 新規タンパク質

Country Status (10)

Country Link
US (1) US20250026805A1 (cg-RX-API-DMAC7.html)
EP (1) EP4426719A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542096A (cg-RX-API-DMAC7.html)
KR (1) KR20240099427A (cg-RX-API-DMAC7.html)
CN (1) CN118369334A (cg-RX-API-DMAC7.html)
AU (1) AU2022381844A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236737A1 (cg-RX-API-DMAC7.html)
GB (1) GB202115803D0 (cg-RX-API-DMAC7.html)
IL (1) IL312470A (cg-RX-API-DMAC7.html)
WO (1) WO2023079278A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
EP1171154A2 (en) 1999-04-13 2002-01-16 Schering Corporation Uses of mammalian ox2 protein and related reagents
WO2008089022A2 (en) 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Similar Documents

Publication Publication Date Title
JP2018527011A5 (cg-RX-API-DMAC7.html)
JP2025515191A5 (cg-RX-API-DMAC7.html)
JP2025000867A5 (cg-RX-API-DMAC7.html)
US11142558B2 (en) Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
ES3031566T3 (en) Tnfr2 agonists with improved stability
AU2017264825B2 (en) CD200 mutant and its uses
CA3258002A1 (en) FCRN BINDING MOLECULES AND METHODS OF USE
JPWO2020209318A5 (cg-RX-API-DMAC7.html)
EP3464347B1 (en) Cysteine-optimized stradomers
JP2022553839A5 (cg-RX-API-DMAC7.html)
JP2017520569A5 (cg-RX-API-DMAC7.html)
JP2024531259A5 (cg-RX-API-DMAC7.html)
US20180194856A1 (en) Fusion proteins which bind to human fc receptors
US20260083671A1 (en) Stabilized formulation comprising recombinant stabilized galectin 9 protein
JP2024546996A5 (cg-RX-API-DMAC7.html)
JP2023513312A5 (cg-RX-API-DMAC7.html)
JP2025516364A5 (cg-RX-API-DMAC7.html)
US20250026805A1 (en) Novel proteins
EP4630445A2 (en) Taci-fc fusion proteins for multifunctional inhibition of baff, april, and neonatal fc receptor
KR20250025619A (ko) 신규한 cd200 융합 단백질
JP2024546654A5 (cg-RX-API-DMAC7.html)
NZ747665B2 (en) Cd200 mutant and its uses
WO2025087363A1 (zh) 用TACI-Fc融合蛋白治疗自身免疫性脑炎的方法
JP2002522355A5 (cg-RX-API-DMAC7.html)
RU2023135361A (ru) Белки, которые связываются с cd80 и/или cd86 и ox40l